EQRx Inc

EQRx — SPAC Merger (August 2021)

39 slides from EQRx's SPAC merger presentation, Aug 6, 2021

  1. Slide 1: New Pharma

    CONFIDENTIAL: DO NOT DISTRIBUTE NEW PHARMA

  2. Slide 2: Disclaimer

    ©EQRx 2021 REMAKING MEDICINE Disclaimer This confidential presentation (“Presentation”) is for informational purposes only and is being provided to interested partie s s olely in their capacities as potential investors and is provided solely for the purpose of allowing interested parties to mak e t

  3. Slide 3: Disclaimer

    ©EQRx 2021 REMAKING MEDICINE Disclaimer This Presentation and any information communicated at any meetings related to your evaluation of the Proposed Transaction are st rictly confidential and should not be discussed outside your organization. No Representations or Warranties. This Presentation is f

  4. Slide 4: Risk factors

    ©EQRx 2021 REMAKING MEDICINE Risk factors All references to “we,” “us” or “our” refer to the business of EQRx prior to the consummation of the Proposed Transaction . The risks described below make up a non - exhaustive list of the key risks related to EQRx’s business and the factors that could cause

  5. Slide 5: Risk factors

    ©EQRx 2021 REMAKING MEDICINE Risk factors • Our success depends in part on broad market acceptance by payers and prescribers of our products if approved, which we may ne ver achieve. • Our success depends on our ability to respond and adapt to changes in the drug development industry and consumer be

  6. Slide 6: EQRx Mission

    EQRx Mission To improve health for all with great, innovative, affordable medicines Such that all can be better – patients can access and afford innovative medicines and health systems can become more financially sustainable 6 ©EQRx 2021 REMAKING MEDICINE

  7. Slide 7: EQRx at a glance today – a starting point

    ©EQRx 2021 REMAKING MEDICINE EQRx at a glance today – a starting point Founded in January 2020, EQRx is purpose - built, at scale, with a growing catalog of medicines in development in high - cost categories (oncology, immunology, etc.) and emerging partnerships with leading payers and providers , t

  8. Slide 8: In the century of biology, it is possible to engineer innovative medicines around almost any target

    ©EQRx 2021 REMAKING MEDICINE In the century of biology, thanks to advances in science and technology, it is possible to engineer innovative medicines around almost any target… Programs commercially available and in development. Source: EvaluatePharma active R&D & commercial programs July 2021 Eviden

  9. Slide 9: Global drug spend and the price of Rx have skyrocketed

    ©EQRx 2021 REMAKING MEDICINE Cost 90’s Today $1T Global Drug Spend* PRICE OF RX Efficiency gains & lower cost base …yet the prices of drugs have skyrocketed *2021 global net prescription drug sales, source: EvaluatePharma July 2020 9 BUSINESS OPPORTUNITY

  10. Slide 10: Time for something new - time for the business model to catch up

    ©EQRx 2021 REMAKING MEDICINE Time for something new - time for the business model to catch up with the medical advances Trusted strategic partnerships Innovative, patented drugs at lower prices with a simple, transparent, “no surprises” pricing model Seamless prescribing, true access for patients, a

  11. Slide 11: A simple yet powerful equation to create New Pharma

    A simple yet powerful equation to create New Pharma Better access to medicines Reduced systemic spend on healthcare Profitable business Fewer program failures Efficient, modern drug development Streamlined, lower cost of commercialization 11 ©EQRx 2021 REMAKING MEDICINE

  12. Slide 12: Illustrative unit economics: profitable business at radically lower prices

    ©EQRx 2021 REMAKING MEDICINE Illustrative unit economics: profitable business at radically lower prices made possible through lower operating costs Model scales through pipeline growth, multiplying these unit economics across a growing pipeline • Significantly reduced price - 50 - 70% lower as an il

  13. Slide 13: And we're just getting started

    ©EQRx 2021 REMAKING MEDICINE And we’re just getting started 10+ programs in pipeline today including 2 pre - registrational assets, expected to rapidly scale to 20+ programs by 2022 and expa nd global payer partnerships Value Two Pre - Registrational Assets Today Positive Phase 3 data for two assets

  14. Slide 14: Health Tech Assessors, Drug Hunters, Developers and Payer Leaders

    ©EQRx 2021 REMAKING MEDICINE To build our Global Buyers’ Club, we have Health Tech Assessors To build our portfolio, we have Drug Hunters and Drug Developers and Regulatory Experts and Payer & PBM Leaders Christoph Lengauer Partner @ Third Rock Ventures, Fmr CSO @ Blueprint Alan Huang CSO @ Tango Th

  15. Slide 15: Mission Advisory Board of world-renowned luminaries

    ©EQRx 2021 REMAKING MEDICINE …and a Mission Advisory Board made up of world - renowned luminaries 15 Otis Webb Brawley, MD Professor of oncology at the Johns Hopkins University School of Medicine and 39th Bloomberg Distinguished Professor at Johns Hopkins Former CMO and CSO of the American Cancer So

  16. Slide 16: EQRx's competitive advantage: boldness of vision and access to capital

    ©EQRx 2021 REMAKING MEDICINE World - class drug hunters and drug developers • Among the best in the industry with decades of experience Building a pipeline and company at scale • We expect 20+ programs by 2022, and 50+ programs by the latter half of the decade, enabled by our funding and purpose - b

  17. Slide 17: Building the pipeline

    ©EQRx 2021 REMAKING MEDICINE Trusted strategic partnerships Seamless prescribing, true access for patients, and a better customer experience for all TRUE ACCESS FOR ALL BETTER VALUE Establishing THE GLOBAL BUYERS’ CLUB via STRATEGIC PARTNERSHIPS with U S and OECD healthcare payers and providers Buil

  18. Slide 18: Current pipeline

    ©EQRx 2021 REMAKING MEDICINE Current pipeline Five disclosed clinical stage programs, plus several undisclosed pre - clinical and drug engineering programs 18 Pre - registrational programs Other late - stage programs Clinical Pre - clinical Drug engineering Aumolertinib (EGFR) Sugemalimab (PD - L1)

  19. Slide 19: Aumolertinib (EGFR)

    ©EQRx 2021 REMAKING MEDICINE Pre - registrational programs Other late - stage programs Clinical Pre - clinical Drug engineering Multiple undisclosed programs … Multiple undisclosed programs … • 3 rd gen EGFR inhibitor (NSCLC), approved in the 2L setting in China (March 2020) • In - licensed from Han

  20. Slide 20: Sugemalimab (PD-L1)

    ©EQRx 2021 REMAKING MEDICINE Pre - registrational programs Other late - stage programs Clinical Pre - clinical Drug engineering … • Anti - PD - L1 monoclonal antibody, being investigated in Ph3 registrational studies in NSCLC (Stage III & IV), Gastric, Esophageal, plus has received BTD for ENKTL • I

  21. Slide 21: Lerociclib (CDK4/6)

    ©EQRx 2021 REMAKING MEDICINE Pre - registrational programs Other late - stage programs Clinical Pre - clinical Drug engineering … • In - licensed from G1 Therapeutics in 2020 • Completed Ph2 study with favorable neutropenia and GI side effect profile compared to competitors • Pivotal studies in meta

  22. Slide 22: Drug engineering collaboration with Exscientia

    ©EQRx 2021 REMAKING MEDICINE Pre - registrational programs Other late - stage programs Clinical Pre - clinical Drug engineering Multiple undisclosed programs … Multiple undisclosed programs • First disclosed collaboration with Exscientia • Multiple other collaborations in discussions 22 Aumolertinib

  23. Slide 23: Targeting blockbusters pressuring healthcare budgets

    ©EQRx 2021 REMAKING MEDICINE Targeting blockbusters pressuring healthcare budgets today and into the future NOW Today’s highest spend categories NEXT Projected blockbusters of the next 5 - 10 years \ FUTURE Streamlined access to excellent medicines throughout the innovation ecosystem Patent - protec

  24. Slide 24: What our catalog of affordable medicines could look like

    ©EQRx 2021 REMAKING MEDICINE ONCOLOGY What our catalog of affordable medicines could look like INFLAMMATION & IMMUNOLOGY PD - L1 BTK CDK4/6 PD - 1 CD38 HER2 EGFR AR Degrader PARP1/2 BCL2 KRASG12C BRAF ALK ROS1 EGFR - MET cMET CD47 SERD BCMA - CD3 TIGIT LAG - 3 EGFR ex20 ER - degrader PARP1 selective

  25. Slide 25: Current portfolio and next year targets

    ©EQRx 2021 REMAKING MEDICINE $200B+ Current Portfolio + Next Year Targets 20+ assets $100B+ Current Portfolio 10+ assets Onc I&I Others In - license Drug engineer. Combos Onc I&I Others In - license Drug engineer. Combos Onc I&I Others In - license Drug engineer. Combos Global drug spend reflects 20

  26. Slide 26: Building the Global Buyers' Club

    ©EQRx 2021 REMAKING MEDICINE Trusted strategic partnerships TRUE ACCESS FOR ALL BETTER VALUE Building the Global Buyers’ Club 26 Via in - licensing and discovery alliances, assembling a CATALOG OF VALIDATED MEDICINES AT SCALE in high - cost categories (oncology, immunology, etc.) BETTER OPTIONS Inno

  27. Slide 27: The New Deal

    ©EQRx 2021 REMAKING MEDICINE The New Deal Incumbent EQRx Partner Our “give”… Price per year …and our “ask” Make it easy for doctors to prescribe through reducing administrative hassles Eliminate or reduce patient out - of - pocket costs Drive adoption of EQRx medicines through a pull model 27

  28. Slide 28: Progress in assembling the Global Buyers' Club

    ©EQRx 2021 REMAKING MEDICINE Progress in assembling the Global Buyers’ Club in the US and internationally 0% 25% 50% 75% 100% In Negotiations Collaboration Agreement In Negotiations Next up Early Discussions In Negotiations Early Discussions Next up In Negotiations Next up Early Discussions U.S. Pay

  29. Slide 29: Example of what our Global Buyers' Club could look like

    ©EQRx 2021 REMAKING MEDICINE OECD and more… UK Canada Denmark Germany Sweden Norway Italy Spain Japan Turkey NZ OTHER REGIONS* MIDDLE EAST & AFRICA SOUTH & CENTRAL AMERICA Example of what our Global Buyers’ Club could look like COMMERCIAL PAYERS Insurer1 Insurer2 Insurer3 Insurer5 Insurer4 Insurer6

  30. Slide 30: Creating the EQRx flywheel

    ©EQRx 2021 REMAKING MEDICINE Invest in pipeline assets to build a catalog of validated medicines at scale TRUE ACCESS FOR ALL Goal for other innovators to place their medicines into our marketplace Truly modern, efficient drug development Drive adoption of EQRx medicines to generate revenue + saving

  31. Slide 31: Projected revenue by program type

    ©EQRx 2021 REMAKING MEDICINE In our early years, the majority of our projected revenue is expected to come from our four lead programs, primarily in oncology 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Projected Annual Revenue by Program Type Drug creation efforts and

  32. Slide 32: Key value inflection points

    ©EQRx 2021 REMAKING MEDICINE Key value inflection points Near - term projected value anchored by two late - stage pre - registrational assets addressing large markets Intrinsic value Pre - registrational programs anchoring value Two pre - registrational assets 10+ pipeline programs Creating the Glob

  33. Slide 33: With additional capital, EQRx can achieve its bold vision

    ©EQRx 2021 REMAKING MEDICINE With additional capital, EQRx can achieve its bold vision The larger the scale, the faster and better the business model works Value 33 NEW PHARMA TRUE ACCESS FOR ALL • Goal is to raise $1.5B through CMLS III + PIPE​ • Build the pipeline & Global Buyers’ Club to scale Se

  34. Slide 34: Thank you

    CONFIDENTIAL: DO NOT DISTRIBUTE Than Q

  35. Slide 35: Overview of CM Life Sciences III

    CONFIDENTIAL ©EQRx 2021 REMAKING MEDICINE Synergistic combination of Eli Casdin’s investment platform and Keith Meister’s capital markets and board expertise 35 Overview of CM Life Sciences III Casdin Capital's Deep Sector Expertise → Founded in 2012, Casdin Capital has a proven track - record as in

  36. Slide 36: Transaction rationale and summary

    CONFIDENTIAL ©EQRx 2021 REMAKING MEDICINE 36 Transaction rationale and summary EQRx opportunity enables investors to participate in the future of pharma, creating value for all stakeholders → Building a “new pharma” led by a world class team of pharma and healthcare professionals → Funding to cataly

  37. Slide 37: Transaction overview: sources and uses

    CONFIDENTIAL ©EQRx 2021 REMAKING MEDICINE 37 Transaction overview Sources and uses ($mm) Note: Analysis assumes no redemptions by CM Life Sciences III public shareholders and excludes the impact from the $500mm EQR x e quity earnout subject to price vesting; values shown assuming $10 per CM Life Sci

  38. Slide 38: Aumolertinib - 3rd-generation EGFR TKI

    Aumolertinib - 3rd - generation EGFR Tyrosine Kinase Inhibitor (TKI) in Adjuvant and 1L EGFR+ NSCLC Aumolertinib - 3rd - generation EGFR inhibitor Mechanism of Action and Key Characteristics Clinical Experience Mechanism of Action Covalent, small - molecule inhibitor that selectively inhibits Exon19

  39. Slide 39: Sugemalimab / CS1001 - immune checkpoint inhibitor

    → 1,600 patients treated across 6 Phase 2 and 3 trials and in 10+ ​ Phase 1a/b trial arms, which include: ​ • Non - small Cell Lung Cancer (NSCLC)​ • Relapsed / refractory extranodal NK/T - Cell Lymphoma (r/r ENKTL)​ • Gastric Cancer, Esophageal Cancer​ • Hodgkin Lymphoma, Bladder Cancer, and additi

EQRx — SPAC Merger (August 2021) on 6ix